Oral News and Research

RSS

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.

21 Jun 2010

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

19 Jun 2010

Research findings support the need to establish standards for DFSA care

New toxicology findings reveal the presence of drugs and/or alcohol in 76 per cent of women and men who suspect they were victims of drug-facilitated sexual assault. Of those, 64 per cent did not report voluntarily consuming the drugs found, supporting their belief that they may have been slipped a drug. In addition, unexpected male DNA was found in a substantial number of cases, confirming sexual activity.

19 Jun 2010

Health Robotics announces new Canadian marketing contracts for i.v.STATION, i.v.SOFT

Health Robotics announced that its joint-venture Health Robotics Canada Inc. (HRCI), a leading Canadian Pharmaceutical Company, and a well-established Quebec-based Medical Device Technology company have all recently signed marketing agreements in order to expand into Canada the market presence of i.v.STATION and i.v.SOFT, revolutionary technologies that provide automated sterile compounding of intravenous medications and parenteral nutrition to hospitals.

19 Jun 2010

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.

19 Jun 2010

SAHM strongly recommends HPV vaccines for males

On May 28, 2010, the Advisory Committee on Immunization Practices published its guidance for use of the quadrivalent HPV vaccine in males. While noting that the vaccine was approved by the FDA for use in males ages 9 through 26 to reduce their likelihood of acquiring genital warts and that it therefore could be given for this purpose, the statement released by ACIP did not recommend routine HPV vaccination of males.

19 Jun 2010

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.

18 Jun 2010

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire Pharmaceuticals, Inc. announced today that data is being presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation and poster presentations at the 33rd Annual European Cystic Fibrosis Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain.

18 Jun 2010

Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that extends the current patent coverage for the Company's MultiStat family of compounds. The forthcoming patent is part of a portfolio that Quick-Med has licensed from the University of Michigan.

18 Jun 2010

U.S. District Court pre-trial ruling favors SPI Pharma in Roquette Freres patent dispute

On Friday June 11th, Chief Judge Gregory Sleet of the United States District Court for the District of Delaware issued an important pre-trial ruling in the long-running patent dispute between SPI Pharma and Roquette Freres.

18 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

One-step surgery positively impacts patient's quality of life: Study

Restoring people's health and returning them to their daily lives as soon as possible is the goal following any surgery. When a person's ability to eat and speak is affected, as with cancer in the mouth, surgery is particularly disruptive, creating a greater challenge. A one-step surgery can remove cancerous tissue and reconstruct bone and teeth functionality immediately, positively impacting the patient's quality of life.

18 Jun 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

18 Jun 2010

New polio strategy builds on 99% drop in Nigeria cases but faces 50% funding shortfall

In Geneva this Friday, a broad range of stakeholders will formally launch the new Strategic Plan 2010-2012 for eradicating wild poliovirus.

18 Jun 2010

If you suffer from sleep apnea, consult with your dentist: PDA

Sleep apnea, a serious and potentially life-threatening disorder if left untreated, affects approximately 18 million Americans. During sleep apnea episodes, a person stops breathing for at least 10 seconds. Depending on the severity of the disorder, a person can have between 10 and 60 episodes a night. Sleep apnea treatment often involves a team of healthcare providers, including dentists, general physicians, surgeons and sleep specialists.

18 Jun 2010

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in an investigator sponsored Phase I/IIa clinical study of AR-42 (formerly OSU-HDAC42) at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) in adult patients with relapsed or refractory multiple myeloma (MM), chronic lymphocytic leukemia (CLL) or lymphoma.

18 Jun 2010

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

Results from a new survey reveal that one in three people with psoriasis do not receive proper treatment for their disease due to health insurance issues—and many won't be helped by the new health care reform law.

17 Jun 2010

First implantation of PyroTITAN Humeral Resurfacing Arthroplasty performed outside US in Australia

Ascension Orthopedics, Inc., a market leader in PyroCarbon orthopedic implants, announces the first implantation of the PyroTITAN™ Humeral Resurfacing Arthroplasty outside the United States. The PyroTITAN was implanted last month in Brisbane, Australia in a 46-year-old patient who reported "immediate pain relief" within 24 hours of surgery. The PyroTITAN Humeral Resurfacing implant is the first commercially-available shoulder arthroplasty prosthesis made of PyroCarbon in the world.

17 Jun 2010

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China focusing on manufacturing and sales of peptide-based and small molecule drugs, today announced that they have obtained the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA).

17 Jun 2010

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Keppra® Injection, levetiracetam injection.

17 Jun 2010

Oral News and Research

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

Research findings support the need to establish standards for DFSA care

Health Robotics announces new Canadian marketing contracts for i.v.STATION, i.v.SOFT

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

SAHM strongly recommends HPV vaccines for males

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

U.S. District Court pre-trial ruling favors SPI Pharma in Roquette Freres patent dispute

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

One-step surgery positively impacts patient's quality of life: Study

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

New polio strategy builds on 99% drop in Nigeria cases but faces 50% funding shortfall

If you suffer from sleep apnea, consult with your dentist: PDA

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

First implantation of PyroTITAN Humeral Resurfacing Arthroplasty performed outside US in Australia

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News